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Abstract 
Peripheral neuropathy is commonly accompanied by cancer but demyelinating ones are not 
commonly reported. We report the clinical, neurophysiological, and biological characteristics 
of an 82-year-old patient who presented with a demyelinating motor neuropathy and high 
titre of anti-ganglioside antibodies associated with oesophageal cancer. The neurological 
course worsened rapidly despite immunotherapy, leading to a bedridden status. We propose 
to suspect a paraneoplastic origin in older patients or when the clinical course progresses 
rapidly within a few weeks or months. 
 
Introduction 
Paraneoplastic neurological syndromes are a heterogeneous group of neurological 
disorders occurring in less than 1% of patients with malignancy [1]. Peripheral 
neuropathy is commonly accompanied by cancer but paraneoplastic neuropathies 
which show a pure demyelinating pattern on electrophysiological studies are not 
commonly reported [2]. 
Case Report 
An 82-year-old patient was referred for a subacute rapidly progressive tetraparesis. He had 
presented with anorexia, asthenia and repeated falls since one month and was admitted 2 weeks ago 
for these complaints in the setting of a biologic inflammatory syndrome. He had no significant past  
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medical history, neither alcohol abuse nor toxic substance exposure nor a significant family history. 
First neurological examination at admission showed a distal paraparesis and lower limb reflex 
abolition. Motor force was otherwise normal. At this time, clinical examination revealed motor deficit 
extension in the proximal areas of the 4 limbs with complete reflex abolition. Sensitive cerebellar and 
cranial nerve examination was normal.  
Electromyography revealed a pure motor demyelinating polyneuropathy of the four limbs with 
several conduction blocks between 55 and 90% in the upper limbs (fig. 1). No motor response was 
detected in the lower limbs and neither tibial F-wave nor H-reflex were recordable (table 1). On 
needle electromyography, we observed denervation potentials in the distal muscles of the four limbs. 
Complete blood count revealed a leucocytosis at 12,000/mm3. Biological tests showed a raised 
C-reactive protein level at 75 mg/l, with normal renal, hepatic and thyroid function tests. HIV serology 
was negative. Cerebrospinal fluid analysis showed 75 leucocytes/mm3 and a hyperproteinorachia at 
1.01 g/l without any malignant cells. Cerebrospinal fluid immunoglobulin dosage showed an elevated 
IgG level of 308 g/l (normal: 10–34). We did not find any Herpesviridae family or Borrelia burgdorferi 
infections. Immunological tests showed anti-GD1a (IgM at 1/2,000 and IgG >1/10,000), anti-GD1b 
IgM at 1/5,000, anti-GM1 IgM at 1/5,000 and onconeural (anti-gray matter and anti-cerebellar) 
antibodies in the serum. Serum protein electrophoresis was normal. 
As an immune-mediated neuropathy was suspected, the patient was treated by one course of IVIg 
(2 g/kg) and corticosteroid pulse without any response to therapy. His general status worsened and 
the patient became bedridden soon thereafter. The presence of onconeural antibodies and general 
status worsening led to a large workup. An oesophageal mass was detected by thoraco-abdomino-
pelvic computed tomography. A transendoscopical biopsy confirmed the diagnosis of epidermoid 
oesophageal carcinoma. At this time, the patient did not have any metastases or any cancer-related 
complaints. Following a multidisciplinary approach, the patient was treated merely by palliative 
radiotherapy and died 4 months later. 
Discussion 
Differential Diagnosis 
The progressive pure motor symptoms in the setting of a demyelinating neuropathy 
associated with conduction blocks in electromyography and presence of a high 
anti-GM1 antibody titre favour the diagnosis of multiple motor neuropathy (MMN). 
However, late-age onset and a 50% decrease in distal amplitude of the sensory ulnar 
nerve are not typical of this diagnosis [3, 4]. 
Initial clinical presentation may be concordant with a motor variant of 
Guillain-Barré syndrome (GBS). Moreover, in a large study of 147 patients with GBS, 
high titres of anti-GM1 antibodies were significantly more common in motor GBS 
patients. However, electrophysiological data of these patients revealed little or no 
evidence for demyelination [5]. High titres of anti-GD1a antibodies have been found in 
patients with GBS but were also found in 18% of patients with MMN and 5% of those 
with chronic inflammatory demyelinating polyneuropathy (CIDP) [6]. 
A chronic (>2 months) course and electrophysiologic findings can raise the 
possibility of CIDP and there are patients eventually diagnosed with CIDP who have an 
acute onset resembling GBS; however, acute-onset CIDP should be suspected in 
patients with prominent sensory symptoms and signs at presentation [7]. 
Conduction blocks are the electrophysiological hallmarks of Lewis and Sumner 
syndrome as well but the major distinguishing features between Lewis and Sumner 
syndrome and motor neuropathy with block are the clinical and electrophysiological  
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sensory involvement and lack of anti-GM1 antibodies in Lewis and Sumner syndrome 
[8]. 
Another paraneoplastic neuropathy which is a classical one is a sensory 
ganglionopathy characterized by non-length-dependent abnormalities of sensory nerve 
action potentials. However, clinical and electrophysiological patterns of our patient did 
not correspond with this entity [9]. 
We could not determine the subtype diagnosis of this demyelinating motor 
neuropathy; based on initial clinical presentation, the diagnosis of GBS was likely but 
the electrophysiological findings are in favour of CIDP or MMN with some atypical 
features. 
Paraneoplastic Origin 
There are different mechanisms by which cancer affects the peripheral nervous 
system (PNS). These mechanisms can include compression or infiltration by the 
tumour, deleterious effects of treatments, metabolic and nutritional factors and 
infections. Paraneoplastic PNS involvements, however, are not explained by any of 
these mechanisms [1]. It has been proposed to classify paraneoplastic PNS disorders as 
definite or possible according to the presence or absence of the following items: 
classical paraneoplastic PNS disorder, onconeural antibodies and development of 
cancer [1, 10]. 
Our patient presented with a non-classical neurological syndrome but the presence 
of onconeural antibodies and cancer occurrence within less than 5 years following 
neurological symptoms confirm the diagnosis of definite paraneoplastic 
polyneuropathy. 
Cases of demyelinating neuropathies in association with solid tumours are rare. GBS 
was reported accompanying endometrial, cholecystic, bronchial, renal, hepatic and 
gastric carcinoma [11–16]. However, in many of these cases, it is difficult to determine 
whether GBS should all the time be considered paraneoplastic because the frequency of 
both cancer and GBS makes a coincidental association possible. There are also reports 
of CIPD associated with solid carcinoma including melanoma, breast, gastric, pancreas, 
liver and colon carcinoma [17–23]. As for GBS, paraneoplastic syndromes are highly 
suggested in these cases but the frequent lack of antineuron antibodies makes the link 
between the two diseases uncertain. To our knowledge, there is no case report of MMN 
associated with cancer. However, in the last decade, there were some reports of MMN 
associated with haematological malignancies [24, 25]. Viala et al. [26] proposed that in 
the setting of demyelinating neuropathies, either a severe or rapid course, a poor 
response to therapy with an early axonal loss or the presence of systemic abnormalities 
should lead to suspect an associated lymphoma. 
It would be interesting to reconsider the course of neuropathy in our patient. The 
neuropathy had a rapid course with early axonal loss witnessed by inexcitability of 
both peroneal and tibial nerves and a poor response to treatment. Unfortunately, in our 
case there was no indication for tumour resection, but the findings in the literature are 
generally consistent with clinical improvement of paraneoplastic demyelinating 
neuropathy following a solid tumour resection [21, 27].  
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Conclusion 
In conclusion, we suggest looking for a paraneoplastic origin in the setting of 
demyelinating neuropathy in older patients, or when the clinical course is progressing 
rapidly within a few weeks or months. 
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Table 1. Results of nerve conduction study 
                    Nerve  Parameter  Normal values  Left side  Right side 
                    Tibial motor  Distal amplitude, mV  >5.9  NR  NR 
  Proximal amplitude, mV    NR  NR 
  Latency, ms  <6.3  NR  NR 
  Conduction velocity, m/s  >44  NR  NR 
                    Peroneal  Distal amplitude, mV  >2.3  NR  NR 
  Proximal amplitude, mV    NR  NR 
  Latency, ms  <5.9  NR  NR 
  Conduction velocity, m/s  >43  NR  NR 
                    Ulnar motor  Distal amplitude W, mV  >4.5  1.3  4.0 
  Proximal amplitude BE, mV    0.192 (86%)*  1.0 (75%)* 
  Proximal amplitude AE, mV    0.083 (57%)*  1.0 
  Proximal amplitude Erb, mV    0.065  0.048 (95%)* 
  Latency, ms  <3.4  2.1  2.8 
  Conduction velocity W – BE, m/s  >50  59.1  46.9 
                    Median motor  Distal amplitude, mV  >5.6  4.3  3.6 
  Proximal amplitude E, mV    2.0 (55%)*  0.46 (87%)* 
  Proximal amplitude Erb, mV    0.18 (91%)*  0.12 (78%)* 
  Latency, ms  <4.0  3.1  3.6 
  Conduction velocity W – E, m/s  >49  50  48 
                    Tibial  F-Wave latency, m/s  <55  NR  NR 
                    Ulnar/median  F-Wave latency, m/s  <28  ND  ND 
                    Sural  Distal amplitude, µV  >3.5  8.1  ND 
  Latency, ms  <3.8  1.7  ND 
  Conduction velocity, m/s  >45  46.8  ND 
                    Ulnar sensory  Distal amplitude, µV  >6.0  ND  3 
  Latency, ms  <3.2  ND  2.8 
  Conduction velocity W – BE, m/s  >47  ND  44.6 
                    Tibial  H-reflex latency, m/s  <34  NR  NR 
                    AE = Above elbow; BE = below elbow; E = elbow; Erb = Erb point; ND = note done; NR = not recordable; 
W = wrist. Abnormal values are in bold. * Conduction block. Decline in negative peak amplitude of the 
motor response is indicated as percentage. 
     
  
Case Rep Neurol 2012;4:71–76 
DOI: 10.1159/000338296 
Published online: 
April 25, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
 
75 
 
 
 
Fig. 1. Conduction block in median nerves. Right limb in the upper half and left limb in the lower one. 
Nerve stimulation at the wrist, elbow and Erb point in an up-to-down order. The decline in negative 
peak amplitude was between 55 and 90% in comparison with distal stimulation. 
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